SEC Form 25-NSE filed

3/8/21 9:24:11 AM ET

$OXFD

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $OXFD alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-36200

Issuer:	Oxford Immunotec Global PLC
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	94C Innovation Drive
	Milton Park Abingdon	UNITED KINGDOM	OX14 4RZ
Telephone number:				+44 (0) 1235 442780

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Ordinary Shares

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2021-03-08	By	Tara Petta		Director
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $OXFD alert in real time by email

SEC Form 25-NSE filed

Chat with this insight

Recent Analyst Ratings for
$OXFD

$OXFD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Herm Rosenman disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: E T Matthew Mclaughlin disposed to the issuer $1,350,954 worth of Ordinary Shares (61,407 units at $22.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: A Richard Sandberg disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

$OXFD
SEC Filings

SEC Form 15-12B filed by Oxford Immunotec Global PLC

SEC Form S-8 POS filed

SEC Form S-8 POS filed

$OXFD
Press Releases

Fastest customizable press release news feed in the world

$OXFD
Financials

Live finance-specific insights

Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea

Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses

Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan

$OXFD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Oxford Immunotec Global PLC

SEC Form SC 13G filed

SEC Form SC 13G/A filed

$OXFD
Leadership Updates

Live Leadership Updates

PerkinElmer to Acquire Oxford Immunotec Global PLC

SEC Form 25-NSE filed

Chat with this insight

Recent Analyst Ratings for $OXFD

$OXFD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Herm Rosenman disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: E T Matthew Mclaughlin disposed to the issuer $1,350,954 worth of Ordinary Shares (61,407 units at $22.00), decreasing direct ownership by 100% to 0 units

SEC Form 4: A Richard Sandberg disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

$OXFD SEC Filings

SEC Form 15-12B filed by Oxford Immunotec Global PLC

SEC Form S-8 POS filed

SEC Form S-8 POS filed

$OXFD Press Releases

Fastest customizable press release news feed in the world

$OXFD Financials

Live finance-specific insights

Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea

Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses

Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan

$OXFD Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Oxford Immunotec Global PLC

SEC Form SC 13G filed

SEC Form SC 13G/A filed

$OXFD Leadership Updates

Live Leadership Updates

PerkinElmer to Acquire Oxford Immunotec Global PLC

Recent Analyst Ratings for
$OXFD

$OXFD
Insider Trading

$OXFD
SEC Filings

$OXFD
Press Releases

$OXFD
Financials

$OXFD
Large Ownership Changes

$OXFD
Leadership Updates